DSM announces patent grants for proprietary XD® biomanufacturing technology

PARSIPPANY, N.J., June 19, 2012 /PRNewswire/ -- DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM N.V. (NYSE, Euronext: DSM KON), announced today that several countries have granted patents or have given statements of patent allowance to its proprietary XD® high cell density process technology.

DSM Biologics focuses on optimizing biopharmaceutical manufacturing through its unique set of technologies. The XD® technology is an important building block in DSM's vision for the future of biopharmaceutical manufacturing. This technology is a highly intensified cell culture process with titer achievement 5-to-15 times higher compared to current standard biomanufacturing processes.  It is widely applicable for multiple products including proteins, fusion proteins and antibodies, and has been successfully employed across the full spectrum of mammalian cell systems. XD® has also shown impressive results for biosimilars and ethical drugs with respect to both volume and product quality.

Karen King, President of DSM Biologics, commented, "Reviews at patent offices across the globe recognized the patentability of DSM's XD® process, amongst others the US and the Eurasian Patent Offices where patents have been granted. Other countries such as South Korea and Australia have provided allowance letters. This is another milestone for DSM Biologics' technology portfolio which can significantly reduce cost, scale-up risk and capital risk of biopharmaceutical manufacturing. The XD® technology offers the opportunity to meet commercial annual demands of 500 kilograms of biopharmaceuticals in a smaller manufacturing footprint than traditional methods. These flexible and cost effective facilities can be easily installed across the globe."

DSM is making the XD® technology available in combination with their contract manufacturing services, and also for license. Licensing includes customer support to set-up the XD® process in-house. The XD® technology is complemented by DSM's proprietary capture and clarification technology called RHOBUST®. Together these technologies significantly optimize the cost and risk profile of current mammalian production processes.

XD® and RHOBUST® are registered trademarks of DSM 

DSM – Bright Science. Brighter Living.™
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 22,000 employees deliver annual net sales of about euro 9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsmbiologics.com and www.dsm.com

Forward-looking statements
This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.

For more information:

SOURCE DSM Pharmaceutical Products